Citrullinated peptides: collagen type -Cit1240, fibrinogen chain-Cit720, fibrinogen chain-Cit436, and vimentin-Cit450
1 injection of low-dose (0.5–1 × 106 cells) or high-dose (2–4.5 × 106 cells)
(i) Grade 1 AE (injection site reactions, transient leucopenia, and headache) (ii) No induction of disease flares and reduction of DAS28 in treated patients (iii) Systemic anti-inflammatory effect based on CRP levels, reduced frequency of Teff, and proinflammatory cytokines and chemokines in treated patients
Addition of dexamethasone and vitamin A to mo-DC cultures
Dose-escalation study: a single or 3 consecutive injections at 2-week intervals of 2 × 106, 5 × 106, and 10 × 106 cells
(i) No AE (3 patients withdrew because of worsening of disease symptoms) (ii) Clinical improvement in 3 out of 13 patients (1 clinical remission, 2 clinical responses) (iii) Increase of circulating Treg and decrease in IFN- levels
We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.